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Abstract: Long-term survival is quite uncommon in refractory small cell lung cancer (SCLC) 
patients, with less than 25% of patients with limited-stage disease and 1%–2% of patients with 
extensive-stage disease remaining alive at five years. Recent clinical studies have demonstrated 
the promising efficacy of amrubicin for patients with relapsed SCLC. This review presents 
the results of clinical studies showing the efficacy and safety of amrubicin for the treatment 
of relapsed SCLC. Amrubicin is a synthetic anthracycline agent with a similar structure to 
  doxorubicin, in which the hydroxyl group at position 9 in amrubicin is replaced by an amino group 
to enhance efficacy. It is converted to an active metabolite, amrubicinol, which is 5–54 times 
more active than amrubicin. Amrubicin and amrubicinol are inhibitors of DNA topoisomerase II, 
exerting their cytotoxic effects by stabilizing a topoisomerase II-mediated cleavable complex. 
The toxicity of amrubicin is similar to that of doxorubicin, although amrubicin shows almost 
no cardiotoxicity. In the relevant trials, amrubicin was administered intravenously at a dose of 
35–40 mg/m2 on days 1–3 every three weeks. The response rate was 34%–52% and median 
survival times were 8.1–12.0 months. Common hematologic toxicities included neutropenia, 
leucopenia, anemia, thrombocytopenia, and febrile neutropenia. Nonhematologic adverse events 
included Grade 3–4 anorexia, asthenia, hyponatremia, and nausea. The results of the studies 
which demonstrated the efficacy of monotherapy for relapsed SCLC involved mainly Japanese 
patients. Therefore, it is necessary to conduct more clinical studies in non-Japanese patients to 
confirm the efficacy of amrubicin.
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Introduction
Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancer cases, 
with two-thirds of patients presenting with extensive disease (ED). Without treatment, 
tumor progression in patients with SCLC is rapid, with a poor prognosis. However, the 
disease shows a high response rate to chemotherapy and radiotherapy, except in a low 
percentage of patients. Treatment options for relapsed SCLC patients remain limited. 
A randomized trial demonstrated that single-agent topotecan was at least as effica-
cious as the three-drug combination of cyclophosphamide-doxorubicin-vincristine for 
the treatment of patients with sensitive relapsed cases.1 Response rates and median 
survival times were 24% and 25.0 weeks for topotecan, and 18% and 24.7 weeks 
for cyclophosphamide-doxorubicin-vincristine, respectively. In previously untreated 
ED-SCLC, amrubicin yielded an extremely high response rate of 79% and a median 
survival time of 11 months, which was comparable with the results achieved with Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
192
Ogawara et al
platinum.2,3 Recently, clinical studies have demonstrated 
the efficacy of amrubicin in patients with relapsed SCLC. 
This review presents the results of clinical studies showing 
the efficacy and safety of amrubicin for the treatment of 
relapsed SCLC.
Structure and characteristics
Amrubicin hydrochloride is a synthetic anthracycline agent, 
with a similar structure to doxorubicin, in which the hydroxyl 
group at position 9 group in amrubicin is replaced by an 
amino group to enhance efficacy (see Figure 1). Amrubicin is 
converted to an active metabolite, amrubicinol, which is 5–54 
times more active than amrubicin, through reduction of its 
C-13 ketone group to a hydroxyl group by carbonyl reductase.4 
Other enzymes metabolizing amrubicin and amrubicinol are 
nicotinamide adenine dinucleotide phosphate (NADPH)-
dependent P450 reductase and NAD[P]H-dependent quinone 
oxidoreductase. Doxorubicin, amrubicin, and amrubicinol are 
inhibitors of DNA topoisomerase II, exerting their cytotoxic 
effects by stabilizing a topoisomerase II-mediated cleavable 
complex.5 In addition, they are more or less only one-tenth as 
potent as doxorubicin in producing DNA intercalation.
Preclinical studies
Antitumor activity and toxicologic aspects were first 
reported for amrubicin by Morisada et al.6 They evaluated 
this agent in six murine systems and nine human tumor-
nude mouse systems, and found that the antitumor activity 
of amrubicin was superior to adriamycin in human tumor 
xenografts, and almost equal against murine experimental 
tumors. They also evaluated toxicity in mice after a bolus 
intravenous injection. The acute toxic signs were body 
weight decrease, ataxia, hair loss, and myelosuppression, 
and these toxicities were qualitatively comparable with 
those induced by adriamycin. The maximum tolerated dose 
was estimated to be 25 mg/kg in four mouse strains, and 
the drug had anticancer activity against human lung cancer 
xenografts in vivo.7
Cardiomyopathy is a burdensome toxicity with the anthra-
cyclines. Suzuki et al evaluated the degree of cardiotoxicity of 
amrubicin compared with that of adriamycin in rabbits.8 The 
drugs were intravenously administered three times a week for 
eight weeks. In this study, prolongation of the QTc interval 
and STT changes were observed in rabbits administered 
amrubicin and adriamycin. Morphologic studies showed that 
myocardial tissue damage in animals administered amrubicin 
was comparable with that seen in controls. Considering the 
results of the antitumor efficacy studies comparing amrubicin 
with adriamycin, they concluded that the cardiotoxicity of 
amrubicin was very slight.
Relapsed small cell lung cancer
Long-term survival is quite uncommon in refractory SCLC 
patients, with less than 25% of patients with limited-stage 
disease and 1%–2% of patients with extensive-stage disease 
remaining alive at five years. A Phase II study was con-
ducted in patients with relapsed disease who had   previously 
received one or two regimens, including at least one regimen 
of platinum-based chemotherapy9 (Table 1). Sixty patients 
were enrolled in this multicenter trial. The disease progressed 
within 60 days after the final dose of previous chemo-
therapy in 16 and 44 refractory patients, respectively. The 
  sensitive groups, in which complete response (CR) or partial 
response (PR) was observed with previous chemotherapy 
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and the disease progressed or relapsed within 60 days of 
the final dose of previous chemotherapy, were eligible for 
the study, and were assessable for toxicity, response, and 
  survival.   Amrubicin was administered intravenously at a dose 
of 40 mg/m2 on days 1–3 every three weeks. The response 
rate was 52% (95% confidence interval [CI] 38%–65%). 
There were no   differences in the response rate, ie, 50% 
(95% CI 25%–75%) for refractory disease and 52% [95% 
CI 37%–68%] for sensitive disease. The median survival 
times were 10.3 months in the refractory group and 11.6 
months in the sensitive group, respectively (P = 0.0974, log 
rank test). Common adverse events were hematologic tox-
icities, including Grade 3–4 neutropenia (83%), leucopenia 
(70%), anemia (33%), thrombocytopenia (20%), and febrile 
neutropenia (5%). Nonhematologic adverse events included 
Grade 3–4 anorexia (15%), asthenia (15%), hyponatremia 
(8%), and nausea (5%).
Another Phase II study of amrubicin in patients with 
previously treated SCLC was conducted by Kaira et al10 
(Table 2). Twenty-nine patients with relapsed SCLC who 
had previously received platinum-based chemotherapy were 
enrolled in the trial, including 10 patients with sensitive 
relapse and 19 patients with refractory relapse. Amrubicin 
was administered intravenously at a dose of 35 mg/m2 on 
days 1–3 every three weeks. The response rate was 44.8% 
(95% CI 26%–64%), being 60% for sensitive cases and 
37% for refractory cases. No significant difference in the 
response rate was observed between sensitive cases and 
relapsed cases (P = 0.233, log rank test). The median 
progression-free   survival and median survival times were 
4.0 months (sensitive relapse, 4.0 months; refractory 
relapse, 4.0 months) and 12.0 months (sensitive relapse, 
12.0 months; refractory relapse, 11.0 months),   respectively. 
There was no difference in median progression-free 
survival and median survival time between sensitive 
relapse and refractory relapse. Grade 3 or 4 neutropenia 
and febrile neutropenia were observed in 42% and 3% of 
patients, respectively. Nonhematologic toxicity higher than 
Grade 3 was not observed. The results of this study show 
the efficacy of monotherapy for relapsed SCLC. However, 
this study involved only Japanese patients, so it would 
be   necessary to conduct clinical studies in non-Japanese 
patients to confirm efficacy.
A randomized Phase II trial of amrubicin versus topo-
tecan as second-line treatment for sensitive ED-SCLC was 
therefore conducted11 (Table 3). Seventy-six patients who 
had previously received platinum-based firstline chemo-
therapy were enrolled. All were sensitive cases, in which 
CR or PR had been observed with previous chemotherapy 
and the disease had then progressed or relapsed within at 
least 90 days of the final dose. Patients were randomized 
at a 2:1 ratio to receive either amrubicin or topotecan. 
Amrubicin was administered intravenously at a dose of 
40 mg/m2 on days 1–3 every three weeks. Topotecan was 
administered intravenously at a dose of 1.5 mg/m2 on days 
1–5 every three weeks. The response rate for amrubicin 
was 34% (95% CI 22%–48%), and for topotecan was 4% 
(95% CI 1%–19%). There was a trend towards a longer 
Table 2 Phase ii trial of amrubicin for treatment of relapsed 
small cell lung cancer10
Sensitive  
cases
Refractory  
cases
Total
Patients (n) 10 19 29
Response rate (%, 95% Ci) 60 37 45 (26–64)
Progression-free  
survival (months)
4 4 4
Median survival time  
(months)
12 11 12
Table 1 Phase ii trial of amrubicin for treatment of refractory or relapsed small cell lung cancer (Thoracic Oncology Research Group 
Study 0301)1
Sensitive cases Refractory  
cases
Total
Patients (n) 44 16 60
CR 1 1 2
PR 22 7 29
SD 10 2 12
PD 11 6 17
Response rate (%, 95% Ci) 52 (37–68) 50 (25%–75%) 52 (38%–65%)
PFS (months, 95% Ci) 42 (10.0–15.8) 2.9 (1.4–4.6) 3.9 (3.4–4.6)
MST (months, 95% Ci) 11.6 (10.0–15.8) 10.3 (4.8–∞) 11.0 (10.0–13.2)
One-year survival (%, 95% Ci) 45.5 (29.9–59.8) 40.3 (15.1–64.6) 44.1 (30.6–56.8)
Abbreviations: CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; MST, median survival time; PFS, 
progression-free survival.Cancer Management and Research 2010:2 submit your manuscript | www.dovepress.com
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progression-free survival time in the amrubicin group 
(4.6 months, 95% CI 64–187) than in the topotecan group 
(3.5 months, 95% CI 75–177). This study showed that 
amrubicin is also active in non-Japanese patients and is well 
tolerated, with myelotoxicity being the main dose-limiting 
toxicity. Inoue et al conducted a randomized Phase II trial 
comparing amrubicin with topotecan in not only sensitive 
relapsed but also refractory cases12 (Table 4). Sensitive 
cases were defined as CR or PR being achieved with the 
previous chemotherapy, after which the disease progressed 
or relapsed at least 90 days after the final dose. Fifty-nine 
patients were randomized in a 1:1 ratio to receive either 
amrubicin or topotecan. Amrubicin was administered 
intravenously at a dose of 40 mg/m2 on days 1–3 every 
three weeks. Topotecan was administered intravenously at 
a dose of 1.0 mg/m2 on days 1–5 every three weeks. The 
response rate for amrubicin was 38% (95% CI 60%–92%) 
and for topotecan was 13% (95% CI 4%–31%). In sensitive 
relapsed cases, the response rate for amrubicin was 53% 
(95% CI 28%–77%), and for topotecan was 21% (95% CI 
6%–46%). In refractory relapsed cases, the response rate for 
amrubicin was 17% (95% CI 2%–48%), and for   topotecan 
was 0% (95% CI 0%–28%). The median   progression-free 
survival time with   amrubicin was 3.5 months and with 
topotecan was 2.2 months. The median overall survival 
time with amrubicin was 8.1 months and with topotecan 
was 8.4 months. There was no difference in the frequency 
of hematologic toxicity more than Grade 3 between amru-
bicin and topotecan. These studies show that amrubicin 
monotherapy is an encouraging regimen for second-line 
treatment of SCLC.
Conclusion
Clinical investigation of the novel anticancer agent, amru-
bicin, has increased quickly, and there are high expectations 
for this agent in trials to improve the outcome for relapsed 
SCLC patients. Amrubicin is an active agent for the treatment 
of relapsed SCLC, but because it is strongly myelotoxic, 
particular care should be taken with its use.
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